Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Semaglutide vs Retatrutide
Peptide Schedule Research TeamReviewed Oct 13, 202612 Citations
Semaglutide (Wegovy, Ozempic) is an FDA-approved GLP-1 receptor agonist. Retatrutide, from Eli Lilly, is an investigational triple agonist of the GLP-1, GIP and glucagon receptors. No head-to-head trial has been published, so every number below comes from separate trials.
14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (PMID 33567185, n=1,961), turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus. The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing. Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT (PMID 37952131) confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants. Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix. In SURMOUNT-5 (PMID 40353578, n=751), semaglutide produced 13.7% weight loss versus 20.2% for tirzepatide at 72 weeks, with everyone on the highest dose they tolerated. Semaglutide holds the stronger cardiovascular outcomes dataset: the SELECT trial (PMID 37952131, n=17,604) confirmed a 20% reduction in major adverse cardiovascular events over 39.8 months.
View full guide →25.0% mean body weight lost at 80 weeks on 12 mg in TRIUMPH-1 (n=2,339, NEJM 2026, PMID 42814954), vs 3.9% on placebo. That peer-reviewed analysis counts everyone randomized, including people who stopped the drug, so it runs lower than on-treatment toplines. The smaller TRIUMPH-4 trial (n=445, December 2025) enrolled adults with obesity and knee osteoarthritis. Its Lilly topline reported 28.7% at 68 weeks and has not been peer-reviewed. No head-to-head trial against tirzepatide or semaglutide exists yet. The retatrutide peptide (LY3437943, CAS 2381089-83-2) is a 39-amino-acid synthetic lipopeptide developed by Eli Lilly. Known in community forums as reta peptide or Triple G, it activates GLP-1, GIP, and glucagon receptors simultaneously in a single molecule. The GLP-1 component suppresses appetite and slows gastric emptying. GIP improves insulin response and buffers GLP-1 tolerability. Glucagon raises resting energy expenditure and burns liver fat directly. That third receptor is the differentiator; dual agonists like tirzepatide lack it entirely. Clinicians and researchers tracking the obesity pharmacotherapy space have been watching retatrutide since the Phase 2 readout (Jastreboff et al., NEJM 2023, PMID 37366315), where 338 adults lost up to 24.2% body weight at 48 weeks on the 12 mg dose. A substudy of that trial in 98 adults with MASLD (Nature Medicine 2024, PMID 38858523) tracked liver fat. On 12 mg, it fell 82.4% from baseline by week 24. More Phase 3 results landed in 2026. In adults with type 2 diabetes, TRIUMPH-2 (n=1,152) found 18.8% weight loss on 12 mg vs 5.1% on placebo at 80 weeks (Lancet 2026, PMID 42810372). TRIUMPH-3, in adults with established cardiovascular disease, reported 22.6% in a Lilly topline (July 2026). Community interest runs highest among people who plateaued on semaglutide or tirzepatide. The enthusiasm is high; so are the GI side effects during dose escalation. Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. Until approval, retatrutide carries no FDA approval and no insurance coverage.
View full guide →At a Glance
| Attribute | ||
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Safety Grade | A | B |
| Half-Life | ~7 days | ~6 days |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 5 mg, 10 mg | 5 mg, 10 mg, 15 mg |
| Beginner Dose | 250 mcg Weekly | 1 mg Weekly |
| Moderate Dose | 500 mcg Weekly | 4 mg Weekly |
| Aggressive Dose | 2.4 mg Weekly | 12 mg Weekly |
| Dosing Source | FDA Label | Clinical Trial |
| Side Effects | Black box warning: semaglutide causes thyroid C-cell tumors in rodents. Whether it causes medullary thyroid carcinoma in humans is unknown. Anyone with a personal or family history of MTC or MEN2 cannot use this drug. That warning is printed on every Wegovy and Ozempic label, and it stays there. GI side effects dominate the titration period. Nausea hits 40 to 50% of patients during the first weeks at each new dose level. For some, that nausea is severe enough to impact daily function and work productivity. Community consensus recommends extending each titration step to 6 to 8 weeks rather than 4 if nausea is bad. The nausea typically fades within the first week at each stable dose. Constipation hit 24% of adults on Wegovy 2.4 mg in the label's weight trials (11% on placebo). Community reports describe it as common with long-term use. Proactive fiber supplementation (psyllium husk from day one) is the top community recommendation. Magnesium citrate at 200 to 400 mg before bed serves as the standard backup. Vomiting and diarrhea also occur, usually transiently during dose escalation. Rare but serious: pancreatitis requires immediate emergency evaluation if you experience severe abdominal pain radiating to the back. Gallbladder disease (cholelithiasis, cholecystitis) is a known complication, particularly with rapid weight loss. Acute kidney injury can result from dehydration driven by persistent GI symptoms. The US labels flag three more signals. Ileus (intestinal obstruction) appears in postmarketing reports and requires emergency care if you develop severe persistent abdominal pain. Diabetic retinopathy complications can paradoxically worsen with rapid A1c improvement in patients with pre-existing retinopathy. Resting heart rate increases a mean 1 to 4 bpm. In the Wegovy weight trials, 26% of users (vs 16% on placebo) had a rise of 20 bpm or more at some visit. NAION (non-arteritic anterior ischemic optic neuropathy) is a separate, rarer eye signal. It's a loss of blood flow to the front of the optic nerve that can cause sudden, painless vision loss, usually in one eye. A 2026 meta-analysis pooled 8 observational cohort studies covering 5,916,559 people (PMID 42612051). Semaglutide users had roughly double the risk (relative effect 1.93, 95% CI 1.22 to 3.08). The studies disagreed widely (I² 91%), and the link was significant in people with diabetes but not in the overweight or obesity subgroup. These are associations, not proof that semaglutide causes NAION. The current US Wegovy, Ozempic, and Rybelsus labels don't list it. Europe's EMA called it a very rare side effect in June 2025 (up to 1 in 10,000 people). Sudden vision loss or fast-worsening eyesight on semaglutide needs same-day medical care. The 7.2 mg Wegovy HD dose introduced a new signal, dysesthesia (altered skin sensation such as tingling or burning). In the label's trials it hit 22% of patients on 7.2 mg, vs 6% on 2.4 mg and 0.3% on placebo. Among those affected, 18% had not recovered by the end of the trial. Hair thinning from telogen effluvium peaks between months 3 and 6. It is a response to rapid weight loss, not a direct drug effect. It typically resolves by month 8 to 12 with adequate protein intake. Lean mass loss of 25 to 40% of total weight lost is documented without resistance training. "Ozempic face" (facial volume loss) becomes visible after 30+ lbs of weight loss. The label contraindications are a personal or family history of MTC or MEN2 and serious hypersensitivity to semaglutide. For weight loss, the label says to stop it in pregnancy, and at least 2 months before a planned pregnancy. It advises against breastfeeding on the tablets and doesn't recommend semaglutide with severe gastroparesis. A history of pancreatitis warrants a talk with your prescriber first. If you are on insulin or sulfonylureas, doses of those drugs typically need a 20 to 30% reduction at semaglutide initiation to prevent hypoglycemia. | Gastrointestinal events during dose escalation are the defining tolerability challenge with retatrutide. Community users often describe them as rougher than on other GLP-1 drugs, though no head-to-head trial has tested that. In TRIUMPH-4 Phase 3 data (Lilly topline 2025), nausea occurred in 38 to 43% of participants. Diarrhea affected 33 to 35%. Constipation hit 22 to 25%. Vomiting was reported in 21%. Side effects led 12.2% on 9 mg and 18.2% on 12 mg to stop, vs 4.0% on placebo. These rates are dose-dependent and front-loaded, meaning they peak during the weeks immediately after each dose increase. Most GI events resolve within 1 to 2 weeks at a stable dose. Stepping up slowly, with 4 weeks between escalations as the Phase 3 trials do, is the standard way to limit them. Raised resting heart rate is the second signal that deserves attention. Phase 2 trials (PMID 37366315) documented a dose-dependent increase in resting HR tied to glucagon receptor activation. Community users at 8 mg and above have reported palpitations and sustained HR above 90 bpm. The TRIUMPH-1 and TRIUMPH-2 abstracts report no heart rate figures, so anyone with a cardiac history should track heart rate weekly during titration. Do not escalate if resting HR stays above 100 bpm. Dysesthesia is the newer Phase 3 signal. It means abnormal skin sensations such as tingling, burning, or numbness. In TRIUMPH-4 it showed up in 8.8% on 9 mg and 20.9% on 12 mg, vs 0.7% on placebo. TRIUMPH-1 reported 5.1 to 12.5% across the 4, 9, and 12 mg doses, vs 0.9% on placebo. Most cases were mild to moderate and resolved during treatment (Lilly topline figures; the TRIUMPH-1 NEJM abstract does not give dysesthesia rates). TRIUMPH-2 (Lancet 2026, PMID 42810372), in 1,152 adults with obesity and type 2 diabetes, flagged low blood pressure. Hypotension hit 1%, 5%, and 6% on 4, 9, and 12 mg vs under 1% on placebo. Dysesthesia ran 4 to 7% vs 1%. Gastrointestinal events were still the most frequent: diarrhea hit 27 to 34% vs 13% on placebo, and nausea 14 to 28% vs 8%. Stopping for side effects or death ran 12% on 9 mg and 8% on 12 mg, vs 4% on 4 mg and 5% on placebo. Lightheadedness on standing is worth a blood pressure check. Post-injection fatigue, sometimes called "wipeout day," shows up consistently in community reports at doses of 8 mg or higher. Users describe pronounced fatigue lasting 12 to 24 hours after injection, particularly during the first 2 to 4 weeks at a new dose level. Scheduling the injection on a low-demand day helps. The GLP-1 class carries an unresolved rodent thyroid C-cell tumor signal. No confirmed human thyroid cancer risk has been established for any GLP-1 agonist, but retatrutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Pancreatitis is a known class risk. Severe persistent abdominal pain radiating to the back warrants immediate medical attention and discontinuation. Pregnancy is an absolute contraindication. No human pregnancy data have been published for retatrutide. Discontinue well before any planned pregnancy. Product quality adds a layer of risk specific to investigational peptides. Retatrutide is not FDA approved; compounded versions lack standardized formulation. A Certificate of Analysis with HPLC purity data is the only check on each batch. Grey-market research chemicals carry contamination and identity risks that cannot be verified. |
Key Differences
Semaglutide activates one receptor, GLP-1. Retatrutide activates three: GLP-1, GIP and glucagon [1]. Both are given as once-weekly injections, and semaglutide also comes as a daily tablet.
TRIUMPH-1 (NEJM 2026)[1] enrolled 2,339 adults with obesity and no diabetes. After 80 weeks, weight fell 17.6% on 4 mg, 23.7% on 9 mg and 25.0% on 12 mg, vs 3.9% on placebo. Semaglutide 2.4 mg produced 14.9% at 68 weeks in STEP 1, vs 2.4% on placebo [2].
The trials ran 68 and 80 weeks, years apart, so the gap between them is an estimate. Against their own placebo arms, the trials reported differences of 21.0 percentage points for retatrutide 12 mg and 12.4 for semaglutide 2.4 mg.
Semaglutide's top dose narrows the gap. Wegovy 7.2 mg, approved March 19, 2026, produced 18.7% at 72 weeks in STEP UP, vs 3.9% on placebo [3]. In retatrutide's phase 2 trial, 12 mg reached 24.2% at 48 weeks [4].
Semaglutide is FDA-approved: Ozempic for type 2 diabetes since December 5, 2017, and Wegovy for weight management since June 4, 2021. Retatrutide has no FDA approval and is still in phase 3 trials.
Fatty liver is where the evidence differs in kind. Wegovy carries an accelerated-approval indication for noncirrhotic MASH with moderate to advanced fibrosis. Retatrutide has a phase 2a substudy of 98 people with fatty liver disease. Liver fat fell 82.4% from baseline at 24 weeks on 12 mg [5].
Gastrointestinal events were the most common side effects in TRIUMPH-1 and in STEP 1. Both drugs raise resting heart rate. The Wegovy label reports a mean rise of 1 to 4 beats per minute over placebo. In retatrutide's phase 2 trial, the rise grew with dose, peaked at 24 weeks, then declined [4].
Dysesthesia, an abnormal skin sensation, shows up with both drugs and climbs with dose. In STEP UP it hit 6.0% on semaglutide 2.4 mg and 22.9% on 7.2 mg, vs 0.5% on placebo [3]. TRIUMPH-2, in adults with obesity and type 2 diabetes, reported 4 to 7% on retatrutide vs 1% on placebo [6]. Low blood pressure hit 1 to 6% on retatrutide in that trial, vs under 1% on placebo. The trials enrolled different people, so these rates do not rank the drugs.
Community reports describe retatrutide as the drug people turn to after a plateau on semaglutide or tirzepatide. Users report faster appetite suppression and rougher nausea during dose steps. Any retatrutide taken outside a trial comes from unregulated sources, so its identity and purity cannot be checked.
When to Choose Semaglutide
An FDA-approved drug with a prescription path is required (Wegovy; Ozempic is for type 2 diabetes)
Heart risk reduction with established heart disease matters (SELECT, 20% fewer major events)[7]
A daily tablet is preferred (Wegovy tablets, approved December 22, 2025)
Fatty liver disease with fibrosis (MASH) is being treated, an indication on the Wegovy label
When to Choose Retatrutide
A clinical trial is an option (retatrutide has no FDA approval)
Weight loss stalled on semaglutide or tirzepatide, a common story in community reports, and a clinical trial is an option
Liver fat is the focus (82.4% relative drop at 24 weeks on 12 mg in a phase 2a substudy)[5]
Verdict
In separate trials, retatrutide produced more weight loss: 25.0% at 80 weeks in TRIUMPH-1 against 14.9% at 68 weeks for semaglutide in STEP 1. Semaglutide is the one with FDA approval, a cardiovascular indication, a tablet and a MASH indication. Community reports treat retatrutide as the next step after a semaglutide or tirzepatide plateau, with rougher nausea during dose steps. Outside a trial, retatrutide comes only from unregulated sources. Until a head-to-head trial reports, the size of the gap stays an estimate.
Research peptides with both sides of the evidence.
Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.
Can You Stack Semaglutide + Retatrutide?
Not together. Retatrutide already activates the GLP-1 receptor, so adding semaglutide stacks two agonists on one receptor. The Wegovy label says coadministration with any other GLP-1 receptor agonist is not recommended. No trial has tested the pair.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Related Guides & Stacks
Peptide Schedule Research TeamReviewed Oct 13, 202612 Citations
References
- [1]TRIUMPH-1: retatrutide for obesity, 80 weeks (NEJM 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]STEP 1: semaglutide 2.4 mg vs placebo, 68 weeks (NEJM 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]STEP UP: once-weekly semaglutide 7.2 mg in adults with obesity (Lancet Diabetes Endocrinol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Retatrutide for obesity, phase 2, 48 weeks (Jastreboff et al., NEJM 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Retatrutide and liver fat: phase 2a substudy in metabolic dysfunction-associated steatotic liver disease (Nat Med 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]TRIUMPH-2: retatrutide in adults with obesity and type 2 diabetes, 80 weeks (Lancet 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]SELECT: semaglutide and cardiovascular outcomes in obesity without diabetes (NEJM 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Wegovy (semaglutide) prescribing information, DailyMed (opens in a new tab)FDA Label
- Drugs@FDA: Ozempic, NDA 209637 (approved December 5, 2017) (opens in a new tab)FDA Label
- Drugs@FDA: Wegovy, NDA 215256 (approved June 4, 2021; 7.2 mg supplement approved March 19, 2026) (opens in a new tab)FDA Label
- Drugs@FDA: Wegovy tablets, NDA 218316 (approved December 22, 2025) (opens in a new tab)FDA Label
- ClinicalTrials.gov NCT06260722: TRANSCEND-T2D-2, retatrutide vs semaglutide in type 2 diabetes, phase 3 (active, no results posted) (opens in a new tab)Clinical Trial